These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 36963656)

  • 21. Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut.
    Papasavas P; Olugbile S; Wu U; Robinson K; Roberts AL; O'Sullivan DM; McLaughlin T; Mather JF; Steinberg AC; Orlando R; Kumar A
    J Hosp Infect; 2021 Aug; 114():117-125. PubMed ID: 33930487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening".
    Jin DK; Nesbitt DJ; Yang J; Chen H; Horowitz J; Jones M; Vandergaast R; Carey T; Reiter S; Russell SJ; Kyratsous C; Hooper A; Hamilton J; Ferreira M; Deng S; Straus D; Baras A; Hillyer CD; Luchsinger LL
    PLoS One; 2021; 16(4):e0250319. PubMed ID: 33909646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.
    Iruretagoyena M; Vial MR; Spencer-Sandino M; Gaete P; Peters A; Delgado I; Perez I; Calderon C; Porte L; Legarraga P; Anderson A; Aguilera X; Vial P; Weitzel T; Munita JM
    BMC Infect Dis; 2021 May; 21(1):478. PubMed ID: 34039287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.
    Skowronski DM; Kaweski SE; Irvine MA; Kim S; Chuang ESY; Sabaiduc S; Fraser M; Reyes RC; Henry B; Levett PN; Petric M; Krajden M; Sekirov I
    CMAJ; 2022 Dec; 194(47):E1599-E1609. PubMed ID: 36507788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
    Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
    Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroconversion rate and socio-economic and ethnic risk factors for SARS-CoV-2 infection in children in a population-based cohort, Germany, June 2020 to February 2021.
    Brinkmann F; Diebner HH; Matenar C; Schlegtendal A; Eitner L; Timmesfeld N; Maier C; Lücke T
    Euro Surveill; 2022 Sep; 27(37):. PubMed ID: 36111557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada.
    Zinszer K; McKinnon B; Bourque N; Zahreddine M; Charland K; Papenburg J; Fortin G; Hamelin MÈ; Saucier A; Apostolatos A; Pierce L; Savard-Lamothe A; Carbonneau J; Conrod P; Haley N; Laurin I; Boivin G; De Serres G; Quach C
    BMJ Open; 2021 Jul; 11(7):e053245. PubMed ID: 34244288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study.
    Lewin A; De Serres G; Grégoire Y; Perreault J; Drouin M; Fournier MJ; Tremblay T; Beaudoin J; Boivin A; Goyette G; Finzi A; Bazin R; Germain M; Delage G; Renaud C
    Can J Public Health; 2022 Jun; 113(3):385-393. PubMed ID: 35380364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
    Letizia AG; Ge Y; Vangeti S; Goforth C; Weir DL; Kuzmina NA; Balinsky CA; Chen HW; Ewing D; Soares-Schanoski A; George MC; Graham WD; Jones F; Bharaj P; Lizewski RA; Lizewski SE; Marayag J; Marjanovic N; Miller CM; Mofsowitz S; Nair VD; Nunez E; Parent DM; Porter CK; Santa Ana E; Schilling M; Stadlbauer D; Sugiharto VA; Termini M; Sun P; Tracy RP; Krammer F; Bukreyev A; Ramos I; Sealfon SC
    Lancet Respir Med; 2021 Jul; 9(7):712-720. PubMed ID: 33865504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does school reopening affect SARS-CoV-2 seroprevalence among school-age children in Milan?
    Barcellini L; Forlanini F; Sangiorgio A; Gambacorta G; Alberti L; Meta A; Gaia P; Amendola A; Tanzi E; Massa V; Borghi E; Fabiano V; Zuccotti GV
    PLoS One; 2021; 16(9):e0257046. PubMed ID: 34473776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study.
    Gebrecherkos T; Kiros YK; Challa F; Abdella S; Gebreegzabher A; Leta D; Desta A; Hailu A; Tasew G; Abdulkader M; Tessema M; Tollera G; Kifle T; Arefaine ZG; Schallig HH; Adams ER; Urban BC; de Wit TFR; Wolday D
    PLoS One; 2022; 17(3):e0263627. PubMed ID: 35320286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saliva SARS-CoV-2 Antibody Prevalence in Children.
    Keuning MW; Grobben M; de Groen AC; Berman-de Jong EP; Bijlsma MW; Cohen S; Felderhof M; de Groof F; Molanus D; Oeij N; Rijpert M; van Eijk HWM; Koen G; van der Straten K; Oomen M; Visser R; Linty F; Steenhuis M; Vidarsson G; Rispens T; Plötz FB; van Gils MJ; Pajkrt D
    Microbiol Spectr; 2021 Oct; 9(2):e0073121. PubMed ID: 34523985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
    Huergo LF; Paula NM; Gonçalves ACA; Kluge CHS; Marins PHSA; Camargo HSC; Sant'Ana TP; Farias LRP; Aldrighi JD; Lima ÊS; Jacotenski GT; Vargas LR; Costa G; Weissheimer KV; Nazário MG; Teixeira KN; Conzentino MS
    Microbiol Spectr; 2022 Aug; 10(4):e0102622. PubMed ID: 35770982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study.
    Shields A; Faustini SE; Perez-Toledo M; Jossi S; Aldera E; Allen JD; Al-Taei S; Backhouse C; Bosworth A; Dunbar LA; Ebanks D; Emmanuel B; Garvey M; Gray J; Kidd IM; McGinnell G; McLoughlin DE; Morley G; O'Neill J; Papakonstantinou D; Pickles O; Poxon C; Richter M; Walker EM; Wanigasooriya K; Watanabe Y; Whalley C; Zielinska AE; Crispin M; Wraith DC; Beggs AD; Cunningham AF; Drayson MT; Richter AG
    Thorax; 2020 Dec; 75(12):1089-1094. PubMed ID: 32917840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Plumb ID; Fette LM; Tjaden AH; Feldstein L; Saydah S; Ahmed A; Link-Gelles R; Wierzba TF; Berry AA; Friedman-Klabanoff D; Larsen MP; Runyon MS; Ward LM; Santos RP; Ward J; Weintraub WS; Edelstein S; Uschner D
    Vaccine; 2023 Apr; 41(15):2596-2604. PubMed ID: 36932031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.
    Reedman CN; Drews SJ; Yi QL; Pambrun C; O'Brien SF
    Microbiol Spectr; 2022 Apr; 10(2):e0033922. PubMed ID: 35412385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study.
    Anand S; Montez-Rath M; Han J; Bozeman J; Kerschmann R; Beyer P; Parsonnet J; Chertow GM
    Lancet; 2020 Oct; 396(10259):1335-1344. PubMed ID: 32987007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study.
    Leidi A; Koegler F; Dumont R; Dubos R; Zaballa ME; Piumatti G; Coen M; Berner A; Darbellay Farhoumand P; Vetter P; Vuilleumier N; Kaiser L; Courvoisier D; Azman AS; Guessous I; Stringhini S;
    Clin Infect Dis; 2022 Mar; 74(4):622-629. PubMed ID: 34043763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.